- Home
- GLTO vs BGLC Comparison
GLTO vs BGLC Comparison
Compare GLTO & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- BGLC
- Stock Information
- Founded
- GLTO 2011
- BGLC 2017
- Country
- GLTO Denmark
- BGLC Malaysia
- Employees
- GLTO N/A
- BGLC N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- GLTO Health Care
- BGLC Health Care
- Exchange
- GLTO Nasdaq
- BGLC Nasdaq
- Market Cap
- GLTO 6.5M
- BGLC 5.8M
- IPO Year
- GLTO 2020
- BGLC N/A
- Fundamental
- Price
- GLTO $4.51
- BGLC $0.35
- Analyst Decision
- GLTO Buy
- BGLC
- Analyst Count
- GLTO 1
- BGLC 0
- Target Price
- GLTO $10.00
- BGLC N/A
- AVG Volume (30 Days)
- GLTO 14.7K
- BGLC 179.2K
- Earning Date
- GLTO 03-07-2025
- BGLC 03-04-2025
- Dividend Yield
- GLTO N/A
- BGLC N/A
- EPS Growth
- GLTO N/A
- BGLC N/A
- EPS
- GLTO N/A
- BGLC N/A
- Revenue
- GLTO N/A
- BGLC $9,259,858.00
- Revenue This Year
- GLTO N/A
- BGLC N/A
- Revenue Next Year
- GLTO N/A
- BGLC N/A
- P/E Ratio
- GLTO N/A
- BGLC N/A
- Revenue Growth
- GLTO N/A
- BGLC N/A
- 52 Week Low
- GLTO $4.24
- BGLC $0.21
- 52 Week High
- GLTO $23.50
- BGLC $1.20
- Technical
- Relative Strength Index (RSI)
- GLTO 39.75
- BGLC 46.44
- Support Level
- GLTO $4.39
- BGLC $0.33
- Resistance Level
- GLTO $4.84
- BGLC $0.40
- Average True Range (ATR)
- GLTO 0.31
- BGLC 0.02
- MACD
- GLTO 0.00
- BGLC -0.01
- Stochastic Oscillator
- GLTO 26.73
- BGLC 23.07
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.